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Summary The practical usefulness of a panel of monoclonal antibodies recognising epithelial and lymphoid
antigens has been evaluated on a series of 10 routinely processed thyroid tumours of uncertain origin.
All 6 small cell tumours were shown to be of lymphoid origin whereas of the 4 large cell tumours two
were lymphomas and two carcinomas. Two of the tumours, one large cell and one small cell, were
undiagnosable due to technical reasons (crush artefact or small size of biopsy) and emphasized the value of
immunohistology in this context. Clinical follow-up of all 10 cases indicated that these distinctions are of both
prognostic and therapeutic value. It is concluded that immunocytochemistry using a carefully selected panel
of monoclonal antibodies is a valuable and convenient means of making an objective distinction between
anaplastic thyroid tumours of epithelial or lymphoid origin.
The pathological discrimination between undif-
ferentiated thyroid carcinomas and lymphomas is
an important but often difficult task. Although
there have been many studies aimed at providing
precise histological and ultrastructural criteria for
thyroid tumours of epithelial and lymphoid ongin
(Cameron et al., 1975; Meissner & Phillips, 1962;
Walt et al., 1957) none of these has proved satis-
factory in routine practice (Williams, 1981). Recent
studies have shown that the use of a carefully
selected panel of monoclonal antibodies is of
practical value in the distinction of carcinoma from
lymphoma (Gatter et al., 1982, 1984). We have
been further assisted by the availability of mono-
clonal antibodies which are able to recognise
antigens of leucocyte, epithelial or other specificities
in conventionally fixed and embedded samples
(Makin et al., 1984; Viac et al., 1983; Warnke et al.,
1983).
In the present study such a panel of monoclonal
antibodies has been used on a series of undif-
ferentiated thyroid tumours to assist in the
distinction between carcinoma and lymphoma. In
addition, all cases have been followed up clinically
to ascertain the value of this diagnostic distinction.
Patients and methods
Patients
Tissue blocks from all of the thyroid neoplasms (10
cases) described as anaplastic and for which clinical
Correspondence: K.C. Gatter.
Received 26 February 1985; and in revised form 11 April
1985.
information was available were recovered from the
files of the Histopathology Department, John
Radcliffe Hospital for the period 1974-1984. All
specimens consisted of conventionally processed
tissue biopsies which had been fixed in formal
saline prior to embedding in paraffin wax.
Monoclonal antibodies
Details of the monoclonal antibodies used in this
study are given in Table I. The specificities of these
reagents have been previously established in this or
other laboratories by immunocytochemical analysis
of a wide range of normal tissues and unequivocal
malignancies (carcinomas, melanomas and lym-
phomas).
Immunoenzymatic techniques
Sections were stained either by a three-stage
immunoperoxidase technique or by the alkaline
Table I Details of monoclonal antibodies
Antibody Specificity Reference
KL1 Cytokeratin Viac, J. et al.
(1983)
5.2 Cytokeratin Makin, C.A. et al.
(1984)
E29 Human milk fat Cordell, J. et al.
globulemembrane (1985)
PD7/26 Leucocyte common Warnke, R.A. et al.
antigen (1983)
2B1 I Leucocyte common Warnke, R.A. et al.
antigen (1983)
CEA Carcinoembryonic Gatter, K.C. et al.
(11.285.14) antigen (1982)
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phosphatase:anti-alkaline phosphatase technique
(APAAP) as described previously (Cordell et al.,
1984; Gatter et al., 1984).
Clinicalfollow-up
The clinical records of the 10 patients all of whom
attended the Radiotherapy Unit, Churchill Hos-
pital, Oxford, were reviewed retrospectively. The
period of follow up ranged from 3 months to 5
years with a mean of 23 months (for the 7 patients
still alive at the time of writing).
Results
Of the 10 cases studied 5 were undifferentiated
small cell tumours, 4 were undifferentiated large
cell tumours and one was a needle biopsy in which
there was an obvious malignant infiltrate but due
to poor preservation it was not possible to
determine the cellular origin (see Table II).
Immunohistological labelling
Details of the immunocytochemical staining results
obtained in the 10 cases in this study are given in
Table II. All 6 cases classified as undifferentiated
small cell tumours were strongly positive with both
of the anti-leucocyte antibodies indicating their
Table II Results of immunocytochemical stainings
Antibodies
Case Histo- Con-
no. logy PD7/26 2BJJ KLI 5.2 E29 CEA clusion
1 SCT + + - - - - lymphoma
2 SCT + + - - - - lymphoma
3 SCT + + - - - - lymphoma
4 SCT + + - - - - lymphoma
5 SCT + + - - - - lymphoma
6 SCT + + - - - - lymphoma
7 LCT + + - - - - lymphoma
8 LCT + + - - - - lymphoma
9 LCT - - + (+) (+) - carcinoma
10 LCT - - + (+) (+) - carcinoma
SCT=small cell tumour; LCT=large cell tumour.
+ =labelling of a majority of the tumour cells;
(+) =labelling of a proportion of the tumour cells.
-=negative.
lymphoid origin. These tumours were negative with
all three anti-epithelial antibodies.
Of the 4 large cell tumours, 2 were classified as
lymphoma due to an identical staining pattern to
the small cell tumours above. The other 2 cases
showed the opposite pattern of staining being
negative with the anti-leucocyte antibodies and
positive with three of the anti-epithelial antibodies.
In both cases the antibody KL1 gave the strongest
and most widespread staining whereas the anti-
cytokeratin CAM 5.2 and anti EMA, (E29) reacted
with a minority of the neoplastic cells. Anti-CEA
was negative in all cases.
Cases 6 and 10 were particularly interesting. Both
were needle biopsies of a thyroid mass which were
so crushed and distorted that it was impossible to
identify the origin of the malignant cells (Figures
lA and B). In both cases staining with the panel of
antibodies showed that the neoplastic cells were
clearly of lymphoid origin, being strongly positive
with both anti-leucocyte antibodies and negative
with all four anti-epithelial markers (Figures 1C-F).
In case 6 the problems were compounded by the
very small size of the biopsy.
Clinicalfollow-up
Table III summarises the data obtained on the 10
patients whose biopsies were examined in this
series. Both of the carcinoma cases have died with
Table III Clinical data
Final Follow
Case Ther- diag- Present up
no. Age Sex Stage' apyb nosis statusc months
1 74 F T s+x lymphoma Do 8
2 65 F T+L x lymphoma Ao 5
3 75 M T+L x lymphoma Ao 19
4 64 F T+L i+x lymphoma Ao 64
5 58 F T x lymphoma Ao 27
6 85 F T+L x lymphoma Ao 24
7 75 F T s+c lymphoma Ao 3
8 85 F T s+x lymphoma Ao 20
9 60 F T s+x+ccarcinoma D+ 16
10 76 F T x carcinoma D+ 3
'T=tumour confined to thyroid; L =local extension.
bs=surgery; x=radiotherapy; i=radioactive iodine.
CA =alive; D=dead; o =without active disease; + =
active disease..n-
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Figure 1 (A) is a needle biopsy of the thyroid (case no. 6) which is diffusely infiltrated by malignant cells
whose origin is unclear due to distortion and crushing; shown at higher power in (B). However, the tumour is
clearly positive for the anti-leucocyte common antigen with PD7/26, illustrated in (C), (E) and (F) and
contrasted with a negative blood vessel (arrow) and 2B11 and negative for cytokeratins with KL1; illustrated
in (D), CAM 5.2, EMA and CEA. A high power view of the leucocyte common positivity shows that even in
the most crushed area of the biopsy(E) the characteristic membranous distribution of the staining can be
appreciated(open arrows). This is demonstrated clearly in slightly less crushed areas (F: open arrows) thus
confirming the lymphoid nature of the tumour. (A) and (B) Haematoxylin and Eosin; (C)-(F)
Immunoperoxidase.
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active disease, whereas 7 of the 8 lymphoma
patients are alive and well, 3 more than 2 years
after diagnosis.
Discussion
The results reported in this study indicate that
using an appropriate panel of monoclonal anti-
bodies, routinely processed undifferentiated thyroid
tumours can be reliably differentiated into carcin-
omas and lymphomas. Furthermore, on reviewing
the clinical course of these patients it seems likely,
although this is only a small series, that this
distinction between carcinoma and lymphoma
is of practical prognostic value.
The origin of small cell undifferentiated thyroid
tumours has been an issue of controversy for some
time. The finding in this study that all five small
cell cases were of lymphoid origin is in keeping
with several other recent clinicopathological surveys
(Compagno & Oentel, 1979; Heimann et al., 1978;
Rayfield et al., 1971; Tobler et al., 1984). However,
a recent immunoperoxidase study of 10 undif-
ferentiated small cell neoplasms of the thyroid
gland suggested that some of these cases were
follicular carcinomas (Mambo & Irwin, 1984). This
underlines the fact that calling a tumour anaplastic
is itself a subjective decision and emphasises the
value of including immunohistopathological
methods in the diagnostic evaluation of poorly
differentiated neoplasms.
Data on large cell thyroid neoplasms is limited
although it is generally assumed that these tumours
are carcinomas. However, in this study two of the
four large cell anaplastic tumours were lymphomas
suggesting that these tumours are equally likely to
be of epithelial or lymphoid origin. Within this
group of large cell tumours case no. 10 illustrates
the particular value of immunocytochemistry in the
evaluation of tumours undiagnosable due to
technical distortion.
In conclusion this study has shown that immuno-
cytochemical techniques utilising a small panel of
monoclonal antibodies should be able to categorise
the vast majority of cases of routinely processed
anaplastic thyroid tumours. In addition, clinical
follow up of these patients indicates that this
differentiation is of prognostic and presumably
therapeutic value although this aspect should be
confirmed on a larger series of patients.
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